Sovalacc | Scientific Publications
11
page,page-id-11,page-template-default,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-7.7,wpb-js-composer js-comp-ver-4.6.2,vc_responsive

Scientific Publications

  • Van de Burgwal, L. H., Reperant, L. A., Osterhaus, A. D., Iancu, S. C., Pronker, E. S., & Claassen, E. (2016). Self-Centric and Altruistic Unmet Needs for Ebola: Barriers to International Preparedness.Disaster Medicine and Public Health Preparedness10(04), 644-648.
  • Rooswinkel, R. W., Berbers, D. S., Claassen, E. H., & van Deventer, S. (2016). Venturing across the Atlantic.Nature biotechnology34(11), 1095-1098.
  • Fernald KDS, Claassen E. Biotech trade sale returns on venture capital – 2010-2014. Nature Biotechnology. In press 2015.
  • Fernald KDS, Hoeben RPN, Claassen E. Venture Capitalists as Gatekeepers for Biotechnological Innovation. Journal of Commercial Biotechnology. 2015.
  • Ramezanpour B, Pronker ES, Kreijtz JH, Osterhaus AD, Claassen E. Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis. Vaccine 2015.
  • Weenen TC, Ramezanpour B, Pronker ES, Commandeur H, Claassen E. Food-Pharma Convergence in Medical Nutrition– Best of Both Worlds? PLoS ONE. 2013;8(12):e82609.
  • Fernald K, Pennings E, Claassen E. Biotechnology Commercialization Strategies: Risk and Return in Interfirm Cooperation. Journal of Product Innovation Management 2015.
  • Pronker E, Weenen T, Commandeur H, Claassen E, Osterhaus ADME. Scratching the surface: Exploratory analysis of key opinion leaders on rate limiting factors in novel adjuvanted-vaccine development. Technological Forecasting and Social Change 2014.
  • Kreijtz JHCM, Ramezanpour B, Fernald KDS, van de Burgwal LHM; 2014; GM vaccines: from bench to bedside; COGEM research report CGM/2014-08.
  • Reperant LA, Van de Burgwal LHM, Claassen E, Osterhaus ADME. Ebola: Public-private partnerships. Science 2014.
  • Fernald KDS, Weenen TC, Sibley KJ, Claassen E. Limits of biotechnological innovation. Technology and Investment 2013.
  • Pronker ES, Weenen TC, Commandeur H, Claassen EHJHM, Osterhaus ADME. Risk in Vaccine Research and Development Quantified. PLoS ONE 2013.
  • Weenen TC, Ramezanpour B, Pronker ES, Commandeur H, Claassen E. Food-Pharma Convergence in Medical Nutrition– Best of Both Worlds? PLoS ONE 2013.
  • Weenen TC, Jentink A, Pronker ES, Commandeur HR, Claassen E. A decision framework to evaluate intellectual property strategies in the medical nutrition market. PharmaNutrition 2013.
  • Weenen TC, Jentink A, Pronker ES, et al. Patient needs and research priorities in the enteral nutrition market – A quantitative prioritization analysis. Clinical nutrition 2013.
  • Weenen TC, Pronker ES, Commandeur HR, Claassen E. Barriers to innovation in the medical nutrition industry: A quantitative key opinion leader analysis. PharmaNutrition 2013.
  • Weenen TC, Pronker ES, Commandeur HR, Claassen E. Patenting in the European medical nutrition industry: Trends, opportunities and strategies. PharmaNutrition 2013.
  • Weenen T, Pronker E, Commandeur H, Claassen E. PP241-sun patenting trends in the European enteral nutrition market. Clinical Nutrition Supplements 2012.
  • Van de Burgwal, L.H. et al., (2010). Succesvol Innoveren: zo financier je dat… PW Magazine 45.